Condition
Autoimmune Epilepsy
Total Trials
3
Recruiting
0
Active
0
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 55/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results50% success
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 3 (1)
Trial Status
Enrolling By Invitation1
Terminated1
Completed1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT07474285Enrolling By InvitationPrimary
Cenobamate Efficacy in Individuals With Autoimmune Epilepsy
NCT05627661Not ApplicableCompletedPrimary
Wearable Devices to Monitor Seizures in Autoimmune Epilepsy
NCT02697292Phase 3TerminatedPrimary
IVIG in Patients With VGKC Ab Associated Autoimmune Epilepsy
Showing all 3 trials